Cancer Family
Malignant Breast Neoplasm
CI-CAN-00000227Explore in graph →
Top-level2,628 active trials43 approved drugs310 evidence items
- NCIt
- C9335
- ICD-10
- C50
- DOID
- 1612
- Other
- 2 more codes
Loading cancer entity…
Cancer Family
CI-CAN-00000227Explore in graph →
Clinical trials
12,359 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,368)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06151249 | Evaluate the Meritup Oral Solution to Decrease Fatigue in Metastatic Breast Cancer Patients Receiving Chemotherapy | unknown | Phase 2 | 32 | Chung Shan Medical UniversityOTHER | 0 | Nov 30, 2023 | clinicaltrials |
| NCT03906669 | A Window of Opportunity Study of Pre-operative Endocrine Therapy With and Without Prometrium in Postmenopausal Women With Early Stage Breast Hormone Receptor Positive (HR+) Human Epidermal Receptor 2 Negative (HER2-) Breast Cancer.(WinPro) | unknown | Phase 2 | 200 | St Vincent's HospitalOTHER |
| 1 |
| Nov 22, 2023 |
| clinicaltrials |
| NCT06088056 | A Phase II Study of T-DXd Plus SRT in HER2-positive Breast Cancer Brain Metastases | unknown | Phase 2 | 17 | Fudan UniversityOTHER | 1 | Oct 18, 2023 | clinicaltrials |
| NCT04267315 | Trigger Point Injections for Post-Mastectomy Pain Syndrome | unknown | Phase 2 | 72 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Oct 16, 2023 | clinicaltrials |
| NCT04591431 | The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy(ROME) | unknown | Phase 2 | 400 | Fondazione per la Medicina PersonalizzataOTHER | 1 | Oct 3, 2023 | clinicaltrials |
| NCT03382340 | IMX-110 in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 70 | Immix Biopharma Australia Pty LtdINDUSTRY | 2 | Sep 28, 2023 | clinicaltrials |
| NCT04883814 | 18F-fluoroestradiol (FES) PET/CT for Breast Cancer | unknown | Phase 2 | 124 | Hoag Memorial Hospital PresbyterianOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT05174832 | Induction of Cisplatin/Nab-paclitaxel/Pembrolizumab Followed by Olaparib/Pembrolizumab Maintenance in mTNBC Patients | unknown | Phase 2 | 136 | Fudan UniversityOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT05800834 | Benefits of Morphine Gel for Pain Reduction in Patients With Cancer Wounds(MorphineGEL) | unknown | Phase 2 | 106 | Instituto Nacional de Cancer, BrazilOTHER_GOV | 1 | Sep 28, 2023 | clinicaltrials |
| NCT05296577 | Anlotinib Combination With Vinorelbine in the HER2- Advanced Breast Cancer | unknown | Phase 2 | 134 | Henan Cancer HospitalOTHER_GOV | 1 | Sep 25, 2023 | clinicaltrials |
| NCT03712956 | CAELYX® as Adjuvant Treatment in Early Stage Luminal B Breast Cancer BREAST CANCER | unknown | Phase 2 | 63 | European Institute of OncologyOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT04165993 | Study of KN026 Monotherapy or Combination Therapy in Patients With Metastatic Breast Cancer | unknown | Phase 2 | 68 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 1 | Sep 21, 2023 | clinicaltrials |
| NCT05353361 | A Phase Ib/II Study of SHR-A1811 Injection in Breast Cancer | unknown | Phase 2 | 402 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Sep 15, 2023 | clinicaltrials |
| NCT05823623 | Inetetamab Combined With Pyrotinib Plus Oral Vinorelbine for the Treatment of HER2-positive Metastatic Breast Cancer | unknown | Phase 2 | 30 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Sep 14, 2023 | clinicaltrials |
| NCT06000033 | Study of Disitamab Vedotin and Anlotinib in Patients With HR-Negative, HER2-Low-Expressing Metastatic Breast Cancer | unknown | Phase 2 | 35 | Qilu Hospital of Shandong UniversityOTHER | 0 | Aug 21, 2023 | clinicaltrials |
| NCT03961698 | Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma(MARIO-3) | unknown | Phase 2 | 91 | Infinity Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 14, 2023 | clinicaltrials |
| NCT05845138 | A Study of SHR-A1811 Combined With Capecitabine in Treatment of Unresectable or Metastatic Breast Cancer With Low HER2 Expression. | unknown | Phase 1 / Phase 2 | 116 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Aug 1, 2023 | clinicaltrials |
| NCT05967884 | PD-1 +/- IL-4 Inhibition in ER+ Breast Cancer | unknown | Phase 2 | 20 | Ottawa Hospital Research InstituteOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT05953168 | T-DXd in the First-Line Treatment of Locally Advanced or Metastatic TNBC-LAR HER2-low Patients | unknown | Phase 2 | 69 | Fudan UniversityOTHER | 1 | Jul 19, 2023 | clinicaltrials |
| NCT05945368 | A Trial of Eribulin in Combination With HP Neoadjuvant Therapy in Patients With for HER2-Positive BC | unknown | Phase 2 | 78 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jul 14, 2023 | clinicaltrials |
| NCT02679040 | Histological Response Rate After Mastectomy and Immediate Breast Reconstruction at the End of Neoadjuvant Chemotherapy and Radiotherapy(HIST-RIC) | unknown | Phase 2 | 101 | Institut Paoli-CalmettesOTHER | 1 | Jul 3, 2023 | clinicaltrials |
| NCT05927779 | Study of TFX06 in Women With Advanced Breast Cancer. | unknown | Phase 1 / Phase 2 | 74 | Zhejiang Yangli Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Jul 3, 2023 | clinicaltrials |
| NCT04304352 | Metronomic Oral Chemotherapy With Cyclophosphamide, Capecitabine and Vinorelbine in Metastatic Breast Cancer Patients(VEX) | unknown | Phase 2 | 162 | European Institute of OncologyOTHER | 1 | Jun 28, 2023 | clinicaltrials |
| NCT05885776 | Preoperative Treatment of HR+/HER2+Breast Cancer With Pirotinib, Trastuzumab and AI Research(PYTHON) | unknown | Phase 2 | 48 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jun 2, 2023 | clinicaltrials |
| NCT03567720 | Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBC | unknown | Phase 2 | 65 | OncoSec Medical IncorporatedINDUSTRY | 2 | Jun 1, 2023 | clinicaltrials |
| NCT05880927 | Pyrotinib After Trastuzumab-based Adjuvant Therapy in Patients With HER2-positive Breast Cancer | unknown | Phase 2 | 150 | Taizhou HospitalOTHER | 1 | May 30, 2023 | clinicaltrials |
| NCT05878678 | Prospective Study of Particle Radiotherapy for Breast Cancer With Different Arm Position | unknown | Phase 2 | 200 | Shanghai Proton and Heavy Ion CenterOTHER | 1 | May 26, 2023 | clinicaltrials |
| NCT05872412 | Effect of Platinum-based Versus Non-platinum-based Neoadjuvant Chemotherapy in Triple-negative Breast Cancer | unknown | Phase 2 | 82 | Bangabandhu Sheikh Mujib Medical University, Dhaka, BangladeshOTHER | 1 | May 25, 2023 | clinicaltrials |
| NCT05763992 | Targeting Triple Negative BREAst Cancer Metabolism With a Combination of Chemoimmunotherapy and a FASTing-like Approach in the Preoperative Setting: the BREAKFAST 2 Trial(BREAKFAST-2) | unknown | Phase 2 | 145 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | May 18, 2023 | clinicaltrials |
| NCT04293276 | Study to Evaluate the Efficacy and Safety of SHR6390 Combined With Pyrotinib in HER2+ Advanced Breast Cancer(DAP-Her-01) | unknown | Phase 2 | 41 | Henan Cancer HospitalOTHER_GOV | 1 | May 6, 2023 | clinicaltrials |
| NCT05833919 | Second Line ERIbulin Followed by CApecitabine or the Reverse Sequence in HER2-negative Metastatic Breast Cancer Patients | unknown | Phase 2 | 122 | Consorzio OncotechOTHER | 1 | Apr 27, 2023 | clinicaltrials |
| NCT04733417 | A Study of SHR6390 Combined With Famitinib in the Treatment of HR + / HER2- Advanced Breast Cancer. | unknown | Phase 2 | 35 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 13, 2023 | clinicaltrials |
| NCT04303741 | A Phase II Trial of Camrelizumab in Combination With Apatinib and Eribulin in Patients With Advanced TNBC | unknown | Phase 2 | 46 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT05556200 | A Phase II Trial of Camrelizumab in Combination With Apatinib for Neoadjuvant Treatment of Early-stage TNBC With a High Proportion of TILs | unknown | Phase 2 | 58 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT05806671 | Dalpiciclib Plus Fulvestrant With Pyrotinib in Hormone Receptor-positive, HER2-low Advanced Breast Cancer That Progressed on Previous CDK4/6i Plus AI Therapy | unknown | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 10, 2023 | clinicaltrials |
| NCT05746728 | Surufatinib Combined With Tislelizumab in the Second-line and Further Treatment of Triple-negative Breast Cancer | unknown | Phase 1 / Phase 2 | 45 | Huihua XiongOTHER | 1 | Apr 6, 2023 | clinicaltrials |
| NCT05800756 | Pyrotinib Combined With Trastuzumab,Dalpiciclib and Letrozole for HR+/HER2+ Breast Cancer | unknown | Phase 2 | 30 | Yantai Yuhuangding HospitalOTHER | 1 | Apr 6, 2023 | clinicaltrials |
| NCT00431704 | VinCaT: Vinorelbine, Carboplatin and Trastuzumab in Advanced Her-2 Positive Breast Cancer(VinCaT) | unknown | Phase 2 | 39 | National Cancer Institute, NaplesOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT05775575 | A Clinical Trial of TQB3909 Tablets in Patients With Breast Cancer | unknown | Phase 1 / Phase 2 | 65 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Mar 20, 2023 | clinicaltrials |
| NCT04924699 | A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer | unknown | Phase 2 / Phase 3 | 350 | Shanghai Miracogen Inc.INDUSTRY | 1 | Mar 17, 2023 | clinicaltrials |
| NCT05429866 | Immunological Variables Associated to ICI Toxicity in Cancer Patients | unknown | Phase 2 | 441 | Jules Bordet InstituteOTHER | 1 | Mar 8, 2023 | clinicaltrials |
| NCT03772353 | Pyrotinib, Dalpiciclib(SHR6390) and Endocrine Therapy in Subjects With Dual-receptor Positive(ER+/HER2+) Advanced Breast Cancer(PLEASURABLE) | unknown | Phase 1 / Phase 2 | 59 | Fudan UniversityOTHER | 1 | Mar 7, 2023 | clinicaltrials |
| NCT03475953 | A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors(REGOMUNE) | unknown | Phase 1 / Phase 2 | 747 | Institut BergoniéOTHER | 1 | Mar 3, 2023 | clinicaltrials |
| NCT05749016 | Neoadjuvant Inetetamab Combined With Pertuzumab and Paclitaxel/Carboplatin for Breast Cancer | unknown | Phase 2 | 30 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Mar 1, 2023 | clinicaltrials |
| NCT05749575 | Chidamide Plus PD-1 Plus Paclitaxel of Neoadjuvant Treatment in Low HR Expression,HER2-negative Early Breast Cancer. | unknown | Phase 2 | 28 | Sun Yat-sen UniversityOTHER | 1 | Mar 1, 2023 | clinicaltrials |
| NCT05670925 | A Trial Exploring the Opportune Administration of Nab-paclitaxel in the First Line Treatment, Camrelizumab Combined With Nab-paclitaxel and Famitinib, of TNBC. | unknown | Phase 2 | 46 | Fudan UniversityOTHER | 1 | Feb 28, 2023 | clinicaltrials |
| NCT05747313 | Chidamide in Combination With Vincristine Metronomic Chemotherapy for Advanced Triple-negative Breast Cancer | unknown | Phase 1 / Phase 2 | 40 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Feb 28, 2023 | clinicaltrials |
| NCT05747326 | Oral Vinorelbine and Capecitabine in Advanced HER2-negative Breast Cancer | unknown | Phase 2 | 30 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Feb 28, 2023 | clinicaltrials |
| NCT04997798 | Dalpiciclib in Combination With Exemestane and Trastuzumab Plus Pyrotinib in Early Triple Positive Breast Cancer | unknown | Phase 2 | 30 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT05430347 | Clinical Study of Pyrotinib in Neoadjuvant Therapy of HR-positive and HER2-positive Breast Cancer | unknown | Phase 2 | 80 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Feb 21, 2023 | clinicaltrials |
Data updated 22 days agoSource updated Nov 30, 2023source: clinicaltrials